GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs.
Quick Facts
What This Study Found
GLP-1 receptor agonists reduced MACE by 14% (HR 0.86), cardiovascular death by 13%, nonfatal stroke by 16%, heart failure hospitalization by 10%, all-cause mortality by 12%, and composite kidney outcome by 17%.
Key Numbers
60,080 patients; 8 CVOTs; HR 0.86 MACE; HR 0.87 CV death; HR 0.84 stroke; HR 0.90 HF hospitalization; HR 0.88 all-cause mortality; HR 0.83 kidney composite
How They Did This
Systematic review and meta-analysis using random-effects model. Electronic search up to June 2021. Included 8 cardiovascular outcome trials (CVOTs) with 60,080 patients total. Hazard ratios with 95% confidence intervals calculated for each outcome.
Why This Research Matters
This is one of the most comprehensive analyses showing GLP-1 drugs do more than control blood sugar. They protect the heart, brain, and kidneys. This supports using these drugs not just for diabetes but for cardiovascular risk reduction.
What This Study Doesn't Tell Us
Meta-analysis pools trials with different GLP-1 drugs, durations, and populations. Benefits were not significantly different between patients with and without existing heart disease, but heterogeneity analysis may be underpowered. Kidney benefit was driven by albumin changes, not hard renal endpoints like dialysis.
Trust & Context
- Original Title:
- GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs.
- Published In:
- Cardiovascular diabetology, 20(1), 189 (2021)
- Authors:
- Giugliano, Dario, Scappaticcio, Lorenzo, Longo, Miriam(2), Caruso, Paola, Maiorino, Maria Ida, Bellastella, Giuseppe, Ceriello, Antonio, Chiodini, Paolo, Esposito, Katherine
- Database ID:
- RPEP-05408
Evidence Hierarchy
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05408APA
Giugliano, Dario; Scappaticcio, Lorenzo; Longo, Miriam; Caruso, Paola; Maiorino, Maria Ida; Bellastella, Giuseppe; Ceriello, Antonio; Chiodini, Paolo; Esposito, Katherine. (2021). GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs.. Cardiovascular diabetology, 20(1), 189. https://doi.org/10.1186/s12933-021-01366-8
MLA
Giugliano, Dario, et al. "GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs.." Cardiovascular diabetology, 2021. https://doi.org/10.1186/s12933-021-01366-8
RethinkPeptides
RethinkPeptides Research Database. "GLP-1 receptor agonists and cardiorenal outcomes in type 2 d..." RPEP-05408. Retrieved from https://rethinkpeptides.com/research/giugliano-2021-glp1-receptor-agonists-and
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.